Showing results (2001-2010 of 2,175) with videos related to

Sort By:
Pageof 218
Circulation. Heart Failure|October 5, 2014
Hypotension during hospitalization for acute heart failure is independently associated with 30-day mortality: findings from ASCEND-HFPriyesh A Patel, Gretchen Heizer, Christopher M O'Connor, et al.
American Heart Journal|December 3, 2014
Routine invasive management early after fibrinolysis: relationship between baseline risk and treatment effects in a pooled patient-level analysis of 7 randomized controlled trialsAkshay Bagai, Mary Tan, Carlo Di Mario, et al.
European Journal of Heart Failure|June 30, 2021
Vericiguat in patients with atrial fibrillation and heart failure with reduced ejection fraction: insights from the VICTORIA trialPiotr Ponikowski, Wendimagegn Alemayehu, Ali Oto, et al.
Life (Basel, Switzerland)|October 26, 2024
Global Comparison of COVID-19 Vaccination Rates among Psoriasis PatientsEdwin Korouri, Charlotte Jeong, Hannah Peterson, et al.
American Heart Journal|March 30, 2013
Radial versus femoral access, bleeding and ischemic events in patients with non-ST-segment elevation acute coronary syndrome managed with an invasive strategyMarc W Klutstein, Cynthia M Westerhout, Paul W Armstrong, et al.
JACC. Heart Failure|December 15, 2015
Prognostic Value of Baseline and Changes in Circulating Soluble ST2 Levels and the Effects of Nesiritide in Acute Decompensated Heart FailureW H Wilson Tang, Yuping Wu, Justin L Grodin, et al.
American Heart Journal|November 14, 2017
Does renal function affect the efficacy or safety of a pharmacoinvasive strategy in patients with ST-elevation myocardial infarction? A meta-analysisJuan J Russo, Shaun G Goodman, Warren J Cantor, et al.
JACC. Cardiovascular Interventions|January 25, 2015
Relationship between time to invasive assessment and clinical outcomes of patients undergoing an early invasive strategy after fibrinolysis for ST-segment elevation myocardial infarction: a patient-level analysis of the randomized early routine invasive clinical trialsMina Madan, Sigrun Halvorsen, Carlo Di Mario, et al.
American Heart Journal|December 3, 2014
Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trialPierluigi Tricoci, Yuliya Lokhnygina, Zhen Huang, et al.
American Heart Journal|August 10, 2016
Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trialLuciana V Armaganijan, Karen P Alexander, Zhen Huang, et al.
Pageof 218